SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
405Exelixis Sells 80% Stake in Artemis to Taconic Nov 20, 2007 13:31:00 (ET) SOULJM-11/20/2007
404Exelixis Announces Third Quarter 2007 Financial Results and Business Update Mondmopgcw-11/7/2007
403>>Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity intuck-10/24/2007
402Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Climopgcw-10/23/2007
401>> In general these arrangements stink for shareholders << It all gscaram(o)uche-10/19/2007
400Definitely similar to the alza/elan r&d shells, pushing expenses off the boorkrw-10/19/2007
399Reminds me of ELN and AZA years ago! JonRobohogs-10/19/2007
398<<So, this means that either EXEL has to let these programs go to Symphonyrkrw-10/16/2007
397Exelixis Announces Transaction to Fund Clinical Development for XL647, XL999 andIcebrg-10/16/2007
396Looks like gsk may wind up passing on all three in the symphony deal. <<rkrw-10/16/2007
395XL784 fails to meet Ph2 Proteinuria endpoint. Article has some details on the GSpgo-neil-10/16/2007
394New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC Monday Octkeokalani'nui-10/8/2007
393English one... karobio.com (edit)... but I'm impressed with your Swedish.nigel bates-9/21/2007
392[OK, now I understand why the Karo/Weyth notice was sort of relevant to EXEL. Bukeokalani'nui-9/21/2007
391Exelixis Research Collaboration With Bristol-Myers Squibb Extended Friday SeptemIcebrg-9/21/2007
390Too bad for Karo, but I cannot see any connection to EXEL. ErikIcebrg-9/21/2007
389UTVECKLINGEN AV DEN KLINISKA KANDIDATEN LXR-623 AVBRUTEN den 20 september 2007 Kkeokalani'nui-9/20/2007
388Submit x748 GSK data pack next. Important from a timing PoV since it's in tkeokalani'nui-9/14/2007
387Exelixis Submits XL880 Diligence Report to GlaxoSmithKline Friday September 14, scaram(o)uche-9/14/2007
386Sept 14 - Lazard Capital Markets began coverage of Exelixis Inc (EXEL.O: Quote, Neil H-9/14/2007
385Exelixis Announces Closing of Public Offering of Common Stock 2007-09-13 11:03 (mopgcw-9/14/2007
384Yeah, the shelf filed and 7 million shares are taken off of it. (Or perhaps fscaram(o)uche-9/10/2007
383DJ teaser to the effect that EXEL is filing for a common stock shelf. sec.gov tuck-9/10/2007
382It was $18.5M upfront, another $4.5M next year and $13M in milestones.rkrw-9/7/2007
381GSK has the right to pick 2-3 out of 10, so inherently they're going to passrkrw-9/5/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News